BI 1467335
Sponsors
Boehringer Ingelheim
Conditions
Diabetic RetinopathyHealthyNon-alcoholic Fatty Liver DiseaseRenal Insufficiency
Phase 1
To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days
CompletedNCT02733627
Start: 2016-07-07End: 2017-07-12Updated: 2021-06-07
This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated
CompletedNCT03159455
Start: 2017-06-07End: 2017-12-16Updated: 2021-06-04
A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body
CompletedNCT03302091
Start: 2017-10-17End: 2018-08-16Updated: 2021-06-04
This Study Tests BI 1467335 in Healthy Male Volunteers. The Study Tests How Different Doses of BI 1467335 Are Taken up and Handled by the Body
CompletedNCT03382509
Start: 2018-01-12End: 2018-04-19Updated: 2021-06-22
This Study in Healthy Men Tests How the Body Takes up BI 1467335
CompletedNCT03483506
Start: 2018-04-10End: 2018-06-27Updated: 2021-07-08
A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.
CompletedNCT03927209
Start: 2019-06-06End: 2019-11-22Updated: 2021-06-22
A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure
TerminatedNCT03979820
Start: 2019-07-31End: 2020-04-08Updated: 2021-06-04
Phase 2
Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH
CompletedNCT03166735
Start: 2017-06-06End: 2019-06-14Updated: 2020-06-11
A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.
CompletedNCT03238963
Start: 2017-09-19End: 2020-05-14Updated: 2021-06-04